Surgical ovarian ablation with bilateral salpingo-oophorectomy is a valuable strategy in the adjuvant therapy of premenopausal breast cancer, particularly among BRCA mutation carriers and women with hormone receptor–positive disease, or among women who find adherence to medical ablation difficult. Patients should be carefully counseled that this may introduce increased long-term cardiovascular risks for them.
Dr. Rossi is an assistant professor in the division of gynecologic oncology at the University of North Carolina at Chapel Hill.
References
1. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1996 Nov 2;348:1189-96.
2. Pagani O et al. N Engl J Med. 2014 Jul 10;371(12):107-18.
3. Francis PA et al. N Engl J Med. 2015 Jan 29;372(5):436-46.
4. Ferrandina G et al. Clin Drug Investig. 2017 Nov;37(11):1093-102.
5. Finch AP et al. J Clin Oncol. 2014 May 20;32(15):1547-53.
6. Shu CA et al. JAMA Oncol. 2016 Nov 1;2(11):1434-40.
7. Parker WH et al. Obstet Gynecol. 2013 Apr;121(4):709-16.
8. Rivera CM et al. Menopause. 2009 Jan-Feb;16:15-23.